Cancers, Volume 17, Issue 14
2025 July-2 - 145 articles
Cover Story: Chronic lymphocytic leukemia (CLL) is a hematologic malignancy characterized by the accumulation of clonal, mature B lymphocytes. Although the introduction of BTK and BCL-2 inhibitors has dramatically improved patient outcomes, resistance to these therapies remains a significant challenge. This review focuses on the latest advances in CLL therapy, particularly novel therapeutic targets under investigation, such as CAR T-cell therapy, T-cell engagers, monoclonal antibodies, antibody–drug conjugates, and novel small-molecule inhibitors, including BTK degraders, MALT1 inhibitors, c-MYC inhibitors, and CDK9 inhibitors. We discuss preclinical and clinical data supporting these strategies and their potential to address unmet needs in double refractory CLL. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.